Vertex Pharmaceuticals Inc (VRTX)

VRTX (NASDAQ:Drugs) EQUITY
$75.78
pos +0.28
+0.37%
Today's Range: 75.25 - 77.33 | VRTX Avg Daily Volume: 1,909,000
Last Update: 12/05/16 - 3:40 PM EST
Volume: 1,666,125
YTD Performance: -35.14%
Open: $76.13
Previous Close: $75.50
52 Week Range: $75.90 - $143.45
Oustanding Shares: 248,033,389
Market Cap: 19,301,958,332
6-Month Chart
TheStreet Ratings Grade for VRTX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 7 9 8
Moderate Buy 2 2 2 2
Hold 8 6 4 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.09 1.90 1.63 1.58
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -86.47
Price Earnings Comparisons:
VRTX Sector Avg. S&P 500
-86.47 0.00 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-14.81% -41.64% 17.56%
GROWTH 12 Mo 3 Yr CAGR
Revenue 77.90 -0.30 -0.12
Net Income 0.00 10.50 0.00
EPS 0.00 3.60 0.00
Earnings for VRTX:
EBITDA -0.40B
Revenue 1.03B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $0.01 $0.07 $-0.23 $0.87
Number of Analysts 7 2 7 3
High Estimate $0.14 $0.12 $-0.10 $1.16
Low Estimate $-0.08 $0.03 $-0.32 $0.60
Prior Year $-0.02 $-0.13 $-2.07 $-0.23
Growth Rate (Year over Year) 135.71% 157.69% 88.68% 472.76%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Buy signals have not lasted more than two months, so far.
Bearish
Nov 29, 2016 | 7:50 AM EST
VRTX was downgraded from Overweight to Equal-weight, Barclays said. $90 price target. Company has an uncertain clinical profile.
What stocks have changed direction in the past week.
These stocks are down some 20% over the last 30 months and look ripe for a rise.
It might be best to make this a late-afternoon purchase.
The answer is that new data came out.
The rate of decline slowed into the base, just what chartists like to see. 
Bullish
Feb 01, 2016 | 7:13 AM EST
VRTX was upgraded from Hold to Buy, Jefferies said. Valuation call, based on a $120 price target.
Bullish
Oct 30, 2015 | 7:26 AM EDT
VRTX was upgraded to Buy, HC Wainwright said. $155 price target. Company has a sound strategy and should continue to execute well. ...
Bullish
Oct 02, 2015 | 7:58 AM EDT
VRTX was upgraded from Equal-weight to Overweight, Morgan Stanley said. Company is transitioning toward profitability and should outper...

Columnist Conversations

BC is moving well today.  Shares are up over 3.5% on fairly heavy trade and are trading at new 2016 highs...
Markets taking the latest rejection of the status quo in Italy in stride as the reforms were expected to lose ...
Merck continues to retreat from November's failed breakout.  Back on 9th and 10th of last month the stock...
Trifecta Stocks name Disney is bumping up to the 100 area hereon some good turnover and bullish flow today (an...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.